Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
This document summarises the Life Saving Drugs Program Expert Panel's consideration of the application from Alexion Pharmaceuticals Australasia Pty Ltd to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of perinatal- and infantile-onset hypophosphatasia (HPP).
The document contains:
- PBAC Consideration
- Consumer Input
- LSDP Expert Panel Consideration
- Funding Criteria
- Pricing Issues
- Treatment Guidelines
- Management of Uncertainties
- Sponsor’s Comment